Advertisement

European Journal of Clinical Pharmacology

, Volume 71, Issue 8, pp 1025–1026 | Cite as

Severe opioid withdrawal syndrome after a single dose of nalmefene

  • Nadine Donnerstag
  • Tobias Schneider
  • Adrian Lüthi
  • Anne Taegtmeyer
  • Alexandra Raetz Bravo
  • Annekathrin Mehlig
Letter to the Editors

Dear Editor,

We would like to present two case reports of severe opioid withdrawal due to drug-drug interaction between the recently approved opioid antagonist nalmefene and opioid in a context of addiction of codeine, respectively methadone.

Case 1

A 43-year-old man was brought by ambulance to the emergency department (ED) with severe agitation and clinical signs of severe opioid withdrawal approximately 2 h after a single dose of nalmefene (Selincro®, Lundbeck (Switzerland)) for his alcohol dependence. His medical history included paranoid schizophrenia, depression, and alcohol and codeine dependence. He consumed up to two bottles of Makatussin® Hustentropfen (Gebropharma AG, Liestal, Switzerland), a codeine-containing cough medicine, per day (equivalent to 636 mg codeine base per day). The psychiatrist who prescribed the nalmefene was unaware of the extent of the patient’s codeine abuse.

The patient needed high bolus doses of midazolam (cumulative dose 25 mg, commenced in the...

Keywords

Clonidine Opioid Antagonist Opioid Withdrawal Nalmefene Opioid Abuse 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Jones HE, Johnson RE, Fudala PJ, Henningfield JE, Heishman SJ (2000) Nalmefene: blockade of intravenous morphine challenge effects in opioid abusing humans. Drug Alcohol Depend 60:29–37PubMedCrossRefGoogle Scholar
  2. 2.
    Product Information Selincro, Lundbeck (Schweiz) AG, Opfikon, Switzerland (2014) Available at http://compendium.ch/prod/selincro-filmtabl-18-mg--ih-07-14-/de
  3. 3.
    Paille F, Martini H (2014) Nalmefene: a new approach to the treatment of alcohol dependence. Subst Abuse Rehabil 5:87–94PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Ingman K, Hagelberg N, Aalto S, Nagren K, Juhakoski A, Karhuvaara S, Kallio A, Oikonen V, Hiertala J, Scheinin H (2005) Prolonged central μ-opioid receptor occupancy after single and repeated nalmefene dosing. Neuropsychopharmacology 12:2245–2253CrossRefGoogle Scholar
  5. 5.
    Wang DS, Sternbach G, Varon J (1998) Nalmefene: a long-acting opioid antagonist. Clinical applications in emergency medicine. J Emerg Med 16:471–475PubMedCrossRefGoogle Scholar
  6. 6.
    Product information Revex, Baxter Deerfield Illinois, USA, 2006; Available at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Department of AnaesthesiologyKantonsspital BasellandLiestalSwitzerland
  2. 2.Department of Clinical Pharmacology & ToxicologyUniversity Hospital and Regional Pharmacovigilance CentreBaselSwitzerland
  3. 3.University Clinic of Internal Medicine, Kantonsspital BasellandUniversity of BaselLiestalSwitzerland

Personalised recommendations